[Treatment results of acute nonlymphocytic leukemia in childhood--Kyushu Yamaguchi Children's Cancer Study Group]

Rinsho Ketsueki. 1995 Apr;36(4):325-33.
[Article in Japanese]

Abstract

Seventy-three children with acute nonlymphocytic leukemia (ANLL) have been treated with ANLL-85 and ANLL-88 protocol at Kyushu-Yamaguchi Children's Cancer Study Group between June, 1985 and February, 1993. Ten boys and 10 girls (0y4m-16ylm) were treated with the ANLL-85 protocol. The complete remission (CR) rate was 75% and the 5-year event free survival (EFS) was 20 +/- 9%. It was terminated because of frequent early relapse (within 6 months after CR). Thirty-four boys and 19 girls (0y3m-17ylm) were treated with the ANLL-88 protocol. The CR rate was 85% and the 5-year EFS was 32 +/- 7%. Early relapse rate with ANLL-88 was lower than that of ANLL-85, however 9 cases relapsed after terminating therapy. Although bone marrow transplantation (BMT) from related donors during the first CR was effective in ANLL-88, EFS was not improved. Recognition of risk factors and appropriate chemotherapy regimens with or without the support of stem cell transplantation may be necessary to cure children with ANLL.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Child
  • Child, Preschool
  • Cyclophosphamide / administration & dosage*
  • Cytarabine / administration & dosage*
  • Daunorubicin / administration & dosage*
  • Drug Administration Schedule
  • Etoposide / administration & dosage*
  • Female
  • Humans
  • Infant
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / mortality
  • Male
  • Mercaptopurine / administration & dosage*
  • Prednisolone / administration & dosage*
  • Recurrence
  • Remission Induction
  • Survival Rate
  • Vincristine / administration & dosage*

Substances

  • Cytarabine
  • Vincristine
  • Etoposide
  • Cyclophosphamide
  • Prednisolone
  • Mercaptopurine
  • Daunorubicin